Selumetinib for treating differentiated thyroid cancer [ID1079]
Discontinued
Reference number: GID-TA10207
Following on from information provided to NICE by the company in December 2017, the appraisal of Selumetinib for treating differentiated thyroid cancer [ID1079] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.